Sedative drugs modulate the neuronal activity in the subthalamic nucleus of parkinsonian patients.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
03 09 2020
03 09 2020
Historique:
received:
28
01
2020
accepted:
10
08
2020
entrez:
5
9
2020
pubmed:
5
9
2020
medline:
9
3
2021
Statut:
epublish
Résumé
Microelectrode recording (MER) is often used to identify electrode location which is critical for the success of deep brain stimulation (DBS) treatment of Parkinson's disease. The usage of anesthesia and its' impact on MER quality and electrode placement is controversial. We recorded neuronal activity at a single depth inside the Subthalamic Nucleus (STN) before, during, and after remifentanil infusion. The root mean square (RMS) of the 250-6000 Hz band-passed signal was used to evaluate the regional spiking activity, the power spectrum to evaluate the oscillatory activity and the coherence to evaluate synchrony between two microelectrodes. We compare those to new frequency domain (spectral) analysis of previously obtained data during propofol sedation. Results showed Remifentanil decreased the normalized RMS by 9% (P < 0.001), a smaller decrease compared to propofol. Regarding the beta range oscillatory activity, remifentanil depressed oscillations (drop from 25 to 5% of oscillatory electrodes), while propofol did not (increase from 33.3 to 41.7% of oscillatory electrodes). In the cases of simultaneously recorded oscillatory electrodes, propofol did not change the synchronization while remifentanil depressed it. In conclusion, remifentanil interferes with the identification of the dorsolateral oscillatory region, whereas propofol interferes with RMS identification of the STN borders. Thus, both have undesired effect during the MER procedure.Trial registration: NCT00355927 and NCT00588926.
Identifiants
pubmed: 32884017
doi: 10.1038/s41598-020-71358-3
pii: 10.1038/s41598-020-71358-3
pmc: PMC7471283
doi:
Substances chimiques
Hypnotics and Sedatives
0
Remifentanil
P10582JYYK
Propofol
YI7VU623SF
Banques de données
ClinicalTrials.gov
['NCT00588926', 'NCT00355927']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14536Références
Hickey, P. & Stacy, M. Deep brain stimulation: a paradigm shifting approach to treat Parkinson’s disease. Front. Neurosci. 10, 173 (2016).
doi: 10.3389/fnins.2016.00173
Kuhn, A. A. et al. High-frequency stimulation of the subthalamic nucleus suppresses oscillatory beta activity in patients with Parkinson’s disease in parallel with improvement in motor performance. J. Neurosci. 28(24), 6165–6173 (2008).
doi: 10.1523/JNEUROSCI.0282-08.2008
Gross,R. E., Krack, P., Rodriguez-Oroz, M. C., Rezai, A. R., & Benabid, A. Electrophysiological mapping for the implantation of deep brain stimulators for Parkinson's disease and tremor. Mov. Dis. 21(S14), 259–283 (2006).
Zaidel, A., Spivak, A., Shpigelman, L., Bergman, H. & Israel, Z. Delimiting subterritories of the human subthalamic nucleus by means of microelectrode recordings and a Hidden Markov Model. Mov. Disord. 24(12), 1785–1793 (2009).
doi: 10.1002/mds.22674
Valsky, D. et al. Stop! border ahead: A utomatic detection of subthalamic exit during deep brain stimulation surgery. Mov. Disord. 32(1), 70–79 (2017).
doi: 10.1002/mds.26806
Hertel, F. et al. Implantation of electrodes fordeep brain stimulation of the subthalamic nucleus in advanced parkinson’s disease with the aid of intraoperative microrecording undergeneral anesthesia. Neurosurgery 59(5), E1138–E1138 (2006).
doi: 10.1227/01.NEU.0000245603.77075.55
Kalenka, A. & Schwarz, A. Anaesthesia and Parkinson’s disease: How to manage with new therapies? Curr. Opin. Anaesthesiol. 22(3), 419–424 (2009).
doi: 10.1097/ACO.0b013e32832a4b31
Bos, M. J., Buhre, W., Temel, Y., Joosten, E. A. J., Absalom, A. R., & Absalom, M. L. F. Effect of anesthesia on microelectrode recordings during deep brain stimulation surgery: A narrative review. J. Neurosurg. Anesth. https://doi.org/10.1097/ANA.0000000000000673 (2020).
Zaidel, A., Spivak, A., Grieb, B., Bergman, H. & Israel, Z. Subthalamic span of β oscillations predicts deep brain stimulation efficacy for patients with Parkinson’s disease. Brain 133(7), 2007–2021 (2010).
doi: 10.1093/brain/awq144
Pogosyan, A., Gaynor, L. D., Eusebio, A. & Brown, P. Boosting cortical activity at beta-band frequencies slows movement in humans. Curr. Biol. 19(19), 1637–1641 (2009).
doi: 10.1016/j.cub.2009.07.074
Kilavik, B. E., Zaepffel, M., Brovelli, A., MacKay, W. A. & Riehle, A. The ups and downs of beta oscillations in sensorimotor cortex. Exp. Neurol. 245, 15–26 (2013).
doi: 10.1016/j.expneurol.2012.09.014
Rubchinsky, L. L., Park, C. & Worth, R. M. Intermittent neural synchronization in Parkinson’s disease. Nonlinear Dyn. 68(3), 329–346 (2012).
doi: 10.1007/s11071-011-0223-z
Heinrichs-Graham, E. et al. Hypersynchrony despite pathologically reduced beta oscillations in patients with Parkinson’s disease: a pharmaco-magnetoencephalography study. J. Neurophysiol. 112(7), 1739–1747 (2014).
doi: 10.1152/jn.00383.2014
Brown P. Bad oscillations in Parkinson’s disease. Parkinson’s Disease and Related Disorders: Springer; 2006. p. 27–30.
Little, S. & Brown, P. The functional role of beta oscillations in Parkinson’s disease. Parkinsonism Relat. Disord. 20, S44–S48 (2014).
doi: 10.1016/S1353-8020(13)70013-0
Kühn, A. A., Kupsch, A., Schneider, G. & Brown, P. Reduction in subthalamic 8–35 Hz oscillatory activity correlates with clinical improvement in Parkinson’s disease. Eur. J. Neurosci. 23(7), 1956–1960 (2006).
doi: 10.1111/j.1460-9568.2006.04717.x
Raz, A., Eimerl, D., Zaidel, A., Bergman, H. & Israel, Z. Propofol decreases neuronal population spiking activity in the subthalamic nucleus of Parkinsonian patients. Anesth. Analg. 111(5), 1285–1289 (2010).
doi: 10.1213/ANE.0b013e3181f565f2
Mathews, L. et al. The effects of dexmedetomidine on microelectrode recordings of the subthalamic nucleus during deep brain stimulation surgery: A retrospective analysis. Stereotact. Funct. Neurosurg. 95(1), 40–48 (2017).
doi: 10.1159/000453326
Lettieri, C. et al. Deep brain stimulation: Subthalamic nucleus electrophysiological activity in awake and anesthetized patients. Clin. Neurophysiol. 123(12), 2406–2413 (2012).
doi: 10.1016/j.clinph.2012.04.027
Moll, C. K. et al. STN stimulation in general anaesthesia Evidence beyond ‘evidence-based medicine’. Stereotactic and functional neurosurgery 19–25 (Springer, Berlin, 2013).
Moshel, S. et al. Subthalamic nucleus long-range synchronization—an independent hallmark of human Parkinson’s disease. Front. Syst. Neurosci. 7, 79 (2013).
doi: 10.3389/fnsys.2013.00079
Chakrabarti, R., Ghazanwy, M. & Tewari, A. Anesthetic challenges for deep brain stimulation: A systematic approach. N. Am. J. Med. Sci. 6(8), 359–369 (2014).
doi: 10.4103/1947-2714.139281
Ho, A. L., Ali, R., Connolly, I. D., Henderson, J. M., Dhall, R., & Stein, S. C., et al. Awake versus asleep deep brain stimulation for Parkinson's disease: A critical comparison and meta-analysis. J. Neurol. Neurosurg. Psychiatry 89(7), 687–691 (2017).
Sheshadri, V. et al. Comparison of general and local anesthesia for deep brain stimulator insertion: A systematic review. Can. J. Neurol. Sci. 44(6), 697–704 (2017).
doi: 10.1017/cjn.2017.224
MacIver, M. B., Bronte-Stewart, H. M., Henderson, J. M., Jaffe, R. A. & Brock-Utne, J. G. Human subthalamic neuron spiking exhibits subtle responses to sedatives. Anesth. J. Am. Soc. Anesthesiol. 115(2), 254–264 (2011).
Michelsen, L. G. & Hug, C. C. Jr. The pharmacokinetics of remifentanil. J. Clin. Anesth. 8(8), 679–682 (1996).
doi: 10.1016/S0952-8180(96)00179-1
Shen, W., Flajolet, M., Greengard, P. & Surmeier, D. J. Dichotomous dopaminergic control of striatal synaptic plasticity. Science 321(5890), 848–851 (2008).
doi: 10.1126/science.1160575
Schroll, H. & Hamker, F. H. Computational models of basal-ganglia pathway functions: Focus on functional neuroanatomy. Front. Syst. Neurosci. 7, 122 (2013).
doi: 10.3389/fnsys.2013.00122
Steiner, H. & Gerfen, C. Enkephalin regulates acute D2 dopamine receptor antagonist-induced immediate-early gene expression in striatal neurons. Neuroscience 88(3), 795–810 (1999).
doi: 10.1016/S0306-4522(98)00241-3
Nisbet, A. et al. Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson’s disease. Neuroscience 66(2), 361–376 (1995).
doi: 10.1016/0306-4522(94)00606-6
Samadi, P., Bédard, P. J. & Rouillard, C. Opioids and motor complications in Parkinson’s disease. Trends Pharmacol. Sci. 27(10), 512–517 (2006).
doi: 10.1016/j.tips.2006.08.002
Morissette, M., Grondin, R., Goulet, M., Bédard, P. J. & Di Paolo, T. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists. J. Neurochem. 72(2), 682–692 (1999).
doi: 10.1046/j.1471-4159.1999.0720682.x
Richardson, S. P. & Egan, T. D. The safety of remifentanil by bolus injection. Expert Opin. Drug Saf. 4(4), 643–651 (2005).
doi: 10.1517/14740338.4.4.643
Jhaveri, R., Joshi, P., Batenhorst, R., Baughman, V. & Glass, P. S. Dose comparison of remifentanil and alfentanil for loss of consciousness. Anesthesiology 87(2), 253–259 (1997).
doi: 10.1097/00000542-199708000-00011
Schüttler, J. et al. A comparison of remifentanil and alfentanil in patients undergoing major abdominal surgery. Anaesthesia 52(4), 307–317 (1997).
doi: 10.1111/j.1365-2044.1997.24-az0051.x
Tomlinson, C. L. et al. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov. Disord. 25(15), 2649–2653. https://doi.org/10.1002/mds.23429 (2010).
doi: 10.1002/mds.23429
pubmed: 21069833